Sign In
Buy EDIT
$2.78
-0.0400 (-1.42%)
At Close: Jun 03, 2026
Editas Medicine, Inc. (EDIT) 6th Annual Evercore ISI HealthCONx Conference (Transcript)
02:36pm, Tuesday, 28'th Nov 2023
Editas Medicine, Inc. (NASDAQ:EDIT ) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 1:20 PM ET Company Participants Erick Lucera - CFO Cristi Barnett - Head, Corporate Communications
CRISPR-Cas9 Gene Editing Is On The Cusp Of Something Big
03:39am, Saturday, 25'th Nov 2023
Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for i
Hidden Gems for Hefty Returns: 3 Stocks Set to Double Your Wealth Next Year
06:30am, Wednesday, 22'nd Nov 2023
On Nov. 25, 2022, I mentioned three stocks to buy that could soar in 2023. At the time, those included Advanced Micro Devices (NASDAQ: AMD ), which ran from $73 to $121.53; Apple (NASDAQ: AAPL ),
The 3 Best Gene Editing Stocks on the Frontier of Medicine
05:43pm, Monday, 20'th Nov 2023
Some of the best gene editing stocks could soon see a massive boost. In just days, the U.S. FDA could approve the first gene-editing treatment of sickle cell disease (SCD) from CRISPR Therapeutics�
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
05:36am, Monday, 20'th Nov 2023
Analysts up and down Wall Street have high expectations for Opera Limited and Editas Medicine. Opera Limited started paying a dividend this year, even though its performance metrics are rising like a
3 Long-Term Growth Stocks Analysts Are Bullish On
03:25pm, Thursday, 16'th Nov 2023
Many investors are experiencing the impact of high inflation and high interest rates for the first time. It's a time when following the daily market news can drive you crazy.
Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript)
05:15pm, Tuesday, 14'th Nov 2023
Editas Medicine, Inc. (NASDAQ:EDIT ) Stifel 2023 Healthcare Conference November 14, 2023 1:50 PM ET Company Participants Erick Lucera - EVP, CFO Cristi Barnett - VP, Corporate Communications and IR Co
3 Biotech Stocks That Are Betting on the Future of Gene Editing
03:37pm, Thursday, 09'th Nov 2023
The fields of gene editing and gene therapy have been growing since the first draft of the human genome map was finished in 2003. In 2022, gaps in that map were completed.
Editas (EDIT) Q3 Earnings & Revenues Beat, Pipeline in Focus
10:32am, Monday, 06'th Nov 2023
Editas' (EDIT) third-quarter 2023 results reflect a year-over-year increase in revenues. The stock of the company rises 18%.
Editas Medicine (EDIT) Reports Q3 Loss, Tops Revenue Estimates
09:47am, Friday, 03'rd Nov 2023
Editas Medicine (EDIT) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.64. This compares to loss of $0.81 per share a year ago.
Company to host a webinar to discuss EDIT-301 clinical data on Monday, December 11, at 1:00 p.m. ET Dr. Rabi Hanna from Cleveland Clinic Children's to present EDIT-301 clinical data at ASH on Monday,
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
07:00am, Friday, 27'th Oct 2023
CAMBRIDGE, Mass., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on F
3 Gene Editing Stocks to Generate Super-Charged Gains
11:05am, Wednesday, 18'th Oct 2023
Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia,
1 Risky Biotech Stock to Consider Buying, and 1 to Avoid
09:30am, Wednesday, 18'th Oct 2023
Don't buy biotech stocks unless your portfolio is properly diversified already. Beam Therapeutics might eventually have a competitive advantage in manufacturing.
Editas (EDIT) Gets FDA's RMAT Tag for Gene Therapy to Treat SCD
01:31pm, Tuesday, 17'th Oct 2023
The FDA bestows Regenerative Medicine Advanced Therapy designation to Editas' (EDIT) gene editing therapy, EDIT-301, for the treatment of severe sickle cell disease. Shares rise.
